Search

Your search keyword '"Mariette, Clara"' showing total 146 results
Start Over Author "Mariette, Clara"
146 results on '"Mariette, Clara"'

1. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Author

Leleu, Xavier, Hulin, Cyrille, Lambert, Jerome, Bobin, Arthur, Perrot, Aurore, Karlin, Lionel, Roussel, Murielle, Montes, Lydia, Cherel, Brieuc, Chalopin, Thomas, Slama, Borhane, Chretien, Marie-Lorraine, Laribi, Kamel, Dingremont, Claire, Roul, Christophe, Mariette, Clara, Rigaudeau, Sophie, Calmettes, Claire, Dib, Mamoun, Tiab, Mourad, Vincent, Laure, Delaunay, Jacques, Santagostino, Alberto, Macro, Margaret, Bourgeois, Emmanuelle, Orsini-Piocelle, Frederique, Gay, Julie, Bareau, Benoit, Bigot, Noemie, Vergez, François, Lebreton, Pierre, Tabrizi, Reza, Waultier-Rascalou, Agathe, Frenzel, Laurent, Le Calloch, Ronan, Chalayer, Emilie, Braun, Thorsten, Lachenal, Florence, Corm, Selim, Kennel, Celine, Belkhir, Rakiba, Bladé, Jean-Sebastien, Joly, Bertrand, Richez-Olivier, Valentine, Gardeney, Helene, Demarquette, Helene, Robu-Cretu, Daniela, Garderet, Laurent, Newinger-Porte, Muriel, Kasmi, Amine, Royer, Bruno, Decaux, Olivier, Arnulf, Bertrand, Belhadj, Karim, Touzeau, Cyrille, Mohty, Mohamad, Manier, Salomon, Moreau, Philippe, Avet-Loiseau, Hervé, Corre, Jill, and Facon, Thierry

Published
2024
Full Text
View/download PDF

2. Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM

Author

Malard, Florent, Bobin, Arthur, Labopin, Myriam, Karlin, Lionel, Frenzel, Laurent, Roussel, Murielle, Vignon, Marguerite, Godet, Sophie, Chalopin, Thomas, Moyer, Perrine, Chalayer, Emilie, Orsini Piocelle, Frederique, Mariette, Clara, Croizier, Carolyne, Sohn, Claudine, Dib, Mamoun, Le Calloch, Ronan, Ali-Ammar, Nadia, Loirat, Marion, Benbrahim, Omar, Payssot, Alexandre, Trebouet, Adrien, Perrot, Aurore, Leleu, Xavier, and Mohty, Mohamad

Published
2024
Full Text
View/download PDF

4. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Author

Roussel, Murielle, Lauwers-Cances, Valérie, Macro, Margaret, Leleu, Xavier, Royer, Bruno, Hulin, Cyrille, Karlin, Lionel, Perrot, Aurore, Touzeau, Cyrille, Chrétien, Marie-Lorraine, Rigaudeau, Sophie, Dib, Mamoun, Nicolas-Virelizier, Emmanuelle, Escoffre-Barbe, Martine, Belhadj, Karim, Mariette, Clara, Stoppa, Anne-Marie, Araujo, Carla, Doyen, Chantal, Fontan, Jean, Kolb, Brigitte, Garderet, Laurent, Brechignac, Sabine, Malfuson, Jean-Valère, Jaccard, Arnaud, Lenain, Pascal, Borel, Cécile, Hebraud, Benjamin, Benbrahim, Omar, Dorvaux, Véronique, Manier, Salomon, Augeul-Meunier, Karine, Vekemans, Marie-Christiane, Randriamalala, Edouard, Chaoui, Driss, Caers, Jo, Chaleteix, Carine, Benboubker, Lofti, Vincent, Laure, Glaisner, Sylvie, Zunic, Patricia, Slama, Borhane, Eveillard, Jean-Richard, Humbrecht-Kraut, Catherine, Morel, Véronique, Mineur, Philippe, Eisenmann, Jean-Claude, Demarquette, Hélène, Richez, Valentine, Vignon, Marguerite, Caillot, Denis, Facon, Thierry, Moreau, Philippe, Colin, Anne-Laurène, Olivier, Pascale, Wuilleme, Soraya, Avet-Loiseau, Hervé, Corre, Jill, and Attal, Michel

Published
2022
Full Text
View/download PDF

5. Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience

Author

Caulier, Alexis, Roussel, Murielle, Morel, Pierre, Lombion, Naelle, Branco, Benoît, Galtier, Jean, Hulin, Cyrille, Perrot, Aurore, Richez, Valentine, Michaud, Anne-Victoire, Touzeau, Cyrille, Doyen, Chantal, Mariette, Clara, Caillot, Denis, Harel, Stéphanie, Lenain, Pascal, Ivanoff, Sarah, Fontan, Jean, Stoppa, Anne-Marie, Manier, Salomon, Garderet, Laurent, Leleu, Xavier, Marolleau, Jean-Pierre, Arnulf, Bertrand, Avet-Loiseau, Hervé, and Royer, Bruno

Published
2021
Full Text
View/download PDF

6. Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Author

Roussel, Murielle, Lauwers-Cances, Valerie, Wuilleme, Soraya, Belhadj, Karim, Manier, Salomon, Garderet, Laurent, Escoffre-Barbe, Martine, Mariette, Clara, Benboubker, Lotfi, Caillot, Denis, Sonntag, Cécile, Touzeau, Cyrille, Dupuis, Jehan, Moreau, Philippe, Leleu, Xavier, Facon, Thierry, Hébraud, Benjamin, Corre, Jill, and Attal, Michel

Published
2021
Full Text
View/download PDF

8. Twice‐weekly induction with ixazomib–lenalidomide–dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant‐eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014‐03

Author

Perrot, Aurore, Roussel, Murielle, Lauwers‐Cances, Valerie, Hulin, Cyrille, Leleu, Xavier, Touzeau, Cyrille, Facon, Thierry, Mariette, Clara, Schiano, Jean‐Marc, Gay, Julie, Montes, Lydia, Ranta, Dana, Huguet, Amandine, Wuillème, Soraya, Dejoie, Thomas, Devlamynck, Laure, Corre, Jill, Avet‐Loiseau, Hervé, Moreau, Philippe, and Attal, Michel

Subjects
MULTIPLE myeloma, LENALIDOMIDE, PERIPHERAL neuropathy, QUADRUPLETS, CLINICAL trials
Abstract

Summary: Therapeutic strategies for patients with newly diagnosed multiple myeloma (NDMM) have considerably improved during the last 10 years. The IFM2014‐03 trial proposed an all‐oral triplet induction/consolidation regimen in transplant‐eligible NDMM patients, followed by lenalidomide maintenance. Induction consisted of three 21‐day cycles of ixazomib, lenalidomide and dexamethasone (IRd), before high‐dose Melphalan with transplant followed by eight 28‐day cycles of IRd consolidation before 13 cycles of lenalidomide maintenance. Forty‐six patients were enrolled and received at least one dose of therapy, and 39 entered the maintenance phase. The primary end‐point was stringent complete response after consolidation, and was achieved in nine patients (20.9%, 90% CI 11.4–33.7; p = 0.998). Ten patients (24.4%) had an undetectable minimal residual disease. The overall response rate was 95.7%. The 3‐year progression‐free survival was 66.3%. No unexpected toxicities were recorded, and only eight patients suspended from any study drug. Of note, 21 (45.7%) patients reported peripheral neuropathy (PN) (grades 1–2 with no serious adverse events). IRd induction and consolidation with transplant before lenalidomide maintenance shows lower response rates compared to other triplet therapies. It could be an alternative for patients who require an all‐oral regimen and/or with pre‐existent PN, especially if quadruplet regimens including anti‐CD38 antibody are not available. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Author

Abildgaard, Niels, Adler, Howard, Altuntas, Fevzi, Akay, Olga Meltem, Amin, Bipinkumar, Anagnostopoulos, Achilleas, Anderson, Larry, Anttila, Pekka, Araujo, Carla, Arce-Lara, Carlos, Aydin, Yildiz, Basu, Supratik, Battini, Ramakrishna, Beeker, Thaddeus, Benboubker, Lotfi, Ben-Yehuda, Dina, Bladé, Joan, Blau, Igor Wolfgang, Boccia, Ralph, Burke, Lillian, Byeff, Peter, Cascavilla, Nicola, Cavo, Michele, Chantry, Andrew, Charles, Yen, Chaudhry, Arvind, Corso, Alessandro, Coyne, Mark, De Arriba, Felipe, Delimpasi, Sosana, Desjardins, Pierre, Dhakal, Binod, Di Bartolomeo, Paolo, Di Raimondo, Francesco, Dürig, Jan, Engelhardt, Monika, Escoffre-Barbe, Martine, Esteves, Graca, Flogegard, Max, Gabrail, Nashat, Gamberi, Barbara, Garrison, Mitchell, Gay, Julie, Gisslinger, Heinz, Goldschmidt, Hartmut, Goncalves, Cristina, Gressot, Laurent, Grosicki, Sebastian, Hanna, Wahid, Hayden, Patrick, Henriques Bernardo, Maria Manuela, Hermann, Robert, Holden, Viran, Honkalehto, Kirsti, Huben, Marianne, Huffman, John, Hunter, Hannah, Hus, Marek, Jagasia, Madan, Jagganath, Sundar, Janakiram, Murali, Jaiyesimi, Ishmael, Jenner, Matthew, João, Cristina, Johnson, Peter, Jurcyszyn, Artur, Kalayoğlu Beşişik, Sevgi, Kambhampati, Suman, Kanate, Abraham, Karadoğan, Ihsan, Khojasteh, Ali, Kirkel, Dean, Komarnicki, Mieczyslaw, Krauth, Maria-Theresa, Kuriakose, Phillip, Larocca, Alessandra, Lauri, Birgitta, Leleu, Xavier, Lucio, Paulo, Luppi, Mario, Mangiacavalli, Silvia, Mariette, Clara, Matsue, Kosei, Mellqvist, Ulf-Henri, Mendeleeva, Larisa, Meshad, Michael, Miller, Carole, Mohrbacher, Ann, Moreau, Philippe, Morelli, Anna Maria, Müldür, Ercan, Naassan, Anthony, Nahi, Hareth, Nair, Rajesh, O'Dwyer, Mike, Öngören Aydin, Seniz, Openshaw, Thomas, O'Rourke, Timothy, Osswald, Michael, Overton, Lindsay, Pati, Asmin, Pavic, Michel, Pegourie, Brigitte, Pehlivan, Mustafa, Pierola, Ana Alfonso, Plesner, Torben, Pluta, Andrzej, Rabin, Neil, Ramasamy, Karthik, Rambaldi, Alessandro, Rodriguez, Paula, Röllig, Christoph, Rosenblatt, Jacalyn, Rosenbluth, Jonathan, Salomo, Morten, Samoylova, Olga, Sastre Moral, Jose, Sati, Hamdi, Selleri, Carmine, Shafeek, Salim, Shinagawa, Atsushi, Sleckman, Bethany, Smith, Clay, Sonmez, Mehmet, Stone, Chester, Streetly, Matthew, Suzuki, Kenshi, Taetle, Raymond, Tafuri, Agostino, Takezako, Naoki, Teke, Hava Üsküdar, Vapaatalo, Mirja, Vassilopoulos, George, Verma, Amit, Vidito, Sarah, Viterbo, Luisa, Vural, Filiz, Wang, Xiang Sean, Yağci, Munci, Yee, Andrew, Richardson, Paul G, Oriol, Albert, Beksac, Meral, Liberati, Anna Marina, Galli, Monica, Schjesvold, Fredrik, Lindsay, Jindriska, Weisel, Katja, White, Darrell, Facon, Thierry, San Miguel, Jesus, Sunami, Kazutaka, O'Gorman, Peter, Sonneveld, Pieter, Robak, Pawel, Semochkin, Sergey, Schey, Steve, Yu, Xin, Doerr, Thomas, Bensmaine, Amine, Biyukov, Tsvetan, Peluso, Teresa, Zaki, Mohamed, Anderson, Kenneth, and Dimopoulos, Meletios

Published
2019
Full Text
View/download PDF

10. Low non‐relapse mortality and good haematological and renal responses after autologous haematopoietic stem cell transplantation in multiple myeloma patients with renal insufficiency at transplant: A prospective Société Francophone de Greffe de Moelle‐Thérapie Cellulaire observational study

Author

Garderet, Laurent, primary, Ouldjeriouat, Hafida, additional, Bekadja, Mohamed‐Amine, additional, Daguenet, Elisabeth, additional, Bigot, Noemie, additional, Vincent, Laure, additional, Roos‐Weil, Damien, additional, Vignon, Marguerite, additional, Ikhlef, Souhila, additional, Abraham, Julie, additional, Escoffre‐Barbe, Martine, additional, Lioure, Bruno, additional, Nacer, Redhouane Ahmed, additional, Lafon, Ingrid, additional, Mariette, Clara, additional, Karlin, Lionel, additional, Morel, Pierre, additional, Gilis, Lila, additional, Le Ray, Emanuelle, additional, Blouet, Anaïse, additional, Nguyen Quoc, Stéphanie, additional, Boffa, Jean Jacques, additional, Ronco, Pierre, additional, Lambert, Jerome, additional, and Cornillon, Jérôme, additional

Published
2023
Full Text
View/download PDF

11. P891: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RRMM PATIENTS: RESULTS OF THE MULTICENTER PHASE 2 STUDY (IFM 2018-02) OF THE INTERGROUPE FRANCOPHONE DU MYÉLOME (IFM).

Author

Macro, Margaret, primary, Touzeau, Cyrille, additional, Mariette, Clara, additional, Manier, Salomon, additional, Brechignac, Sabine, additional, Vincent, Laure, additional, Hebraud, Benjamin, additional, Decaux, Olivier, additional, Schulmann, Samantha, additional, Lenoir, Caroline, additional, Godmer, Pascal, additional, Farge, Agathe, additional, Paul, Laure Peyro Saint, additional, Parienti, Jean-Jacques, additional, and Leleu, Xavier, additional

Published
2023
Full Text
View/download PDF

12. Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up

Author

Paillassa, Jerome, Cornet, Edouard, Noel, Stephanie, Tomowiak, Cecile, Lepretre, Stephane, Vaudaux, Sandrine, Dupuis, Jehan, Devidas, Alain, Joly, Bertrand, Petitdidier-Lionnet, Charlotte, Haiat, Stephanie, Mariette, Clara, Thieblemont, Catherine, Decaudin, Didier, Validire-Charpy, Patricia, Drenou, Bernard, Eisenmann, Jean-Claude, Uribe, Mario Ojeda, Olivrie, Agnès, Touati, Mohamed, Lambotte, Olivier, Hermine, Olivier, Karsenti, Jean-Michel, Feugier, Pierre, Vaillant, Willy, Gutnecht, Jean, Lippert, Eric, Huysman, Fabienne, Ghomari, Kamel, Boubaya, Marouane, Levy, Vincent, Riou, Jeremie, Damaj, Gandhi, Tanguy-Schmidt, Aline, Hunault-Berger, Mathilde, and Troussard, Xavier

Published
2020
Full Text
View/download PDF

13. Low non‐relapse mortality and good haematological and renal responses after autologous haematopoietic stem cell transplantation in multiple myeloma patients with renal insufficiency at transplant: A prospective Société Francophone de Greffe de Moelle‐Thérapie Cellulaire observational study

Author

Garderet, Laurent, Ouldjeriouat, Hafida, Bekadja, Mohamed‐Amine, Daguenet, Elisabeth, Bigot, Noemie, Vincent, Laure, Roos‐Weil, Damien, Vignon, Marguerite, Ikhlef, Souhila, Abraham, Julie, Escoffre‐Barbe, Martine, Lioure, Bruno, Nacer, Redhouane Ahmed, Lafon, Ingrid, Mariette, Clara, Karlin, Lionel, Morel, Pierre, Gilis, Lila, Le Ray, Emanuelle, and Blouet, Anaïse

Subjects
HEMATOPOIETIC stem cell transplantation, KIDNEY failure, KIDNEY transplantation, MULTIPLE myeloma, AUTOTRANSPLANTATION
Abstract

Summary: High‐dose melphalan followed by autologous haematopoietic stem cell transplantation is widely used in newly diagnosed multiple myeloma (MM) patients as upfront therapy. However, the safety and efficacy of transplantation in patients with renal insufficiency (RI) are controversial. We followed a multicentre (16 SFGM‐TC centres) prospective cohort of 50 newly diagnosed MM patients with a serum creatinine clearance of <40 mL/min at transplantation. Patients received a recommended dose of melphalan of 140 mg/m2. The primary end‐point was the non‐relapse mortality at Day 100. One death occurred during the first 100 days post‐transplant. The median time to neutrophil engraftment was 12 days and to platelet engraftment was 13 days. The haematological response improved in 69% of patients, with best responses from partial response (PR) to very good partial response (VGPR) (10%), from PR to complete response (CR)/stringent complete response (sCR) (16%), from VGPR to CR/sCR (39%) and from CR to sCR (2%). At 2 years, the overall survival was 84%, the progression‐free survival was 70% and the cumulative incidence of relapse was 20%. The renal response improved in 59% of patients, with the best renal responses post‐transplant being minimal (9%), partial (2%) and complete (48%). Autologous transplantation was safe and effective in myeloma patients with RI at transplant. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial

Author

Ribrag, Vincent, Koscielny, Serge, Bosq, Jacques, Leguay, Thibaut, Casasnovas, Olivier, Fornecker, Luc-Mathieu, Recher, Christian, Ghesquieres, Hervé, Morschhauser, Franck, Girault, Stéphane, Gouill, Steven Le, Ojeda-Uribe, Mario, Mariette, Clara, Cornillon, Jerome, Cartron, Guillaume, Verge, Veronique, Chassagne-Clément, Catherine, Dombret, Hervé, Coiffier, Bertrand, Lamy, Thierry, Tilly, Hervé, and Salles, Gilles

Published
2016
Full Text
View/download PDF

15. Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Dumontet, Charles, Demangel, Delphine, Galia, Perrine, Karlin, Lionel, Roche, Laurent, Fauvernier, Mathieu, Golfier, Camille, Laude, Marie-Charlotte, Leleu, Xavier, Rodon, Philippe, Roussel, Murielle, Azaïs, Isabelle, Doyen, Chantal, Slama, Borhane, Manier, Salomon, Decaux, Olivier, Pertesi, Maroulio, Beaumont, Marie, Caillot, Denis, Boyle, Eileen M, Cliquennois, Manuel, Cony-Makhoul, Pascale, Doncker, Anne-Violaine, Dorvaux, Véronique, Petillon, Marie Odile, Fontan, Jean, Hivert, Bénédicte, Leduc, Isabelle, Leyronnas, Cécile, Macro, Margaret, Maigre, Michel, Mariette, Clara, Mineur, Philippe, Rigaudeau, Sophie, Royer, Bruno, Vincent, Laure, Mckay, James, Perrial, Emeline, Garderet, Laurent, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Dumontet, Charles, Demangel, Delphine, Galia, Perrine, Karlin, Lionel, Roche, Laurent, Fauvernier, Mathieu, Golfier, Camille, Laude, Marie-Charlotte, Leleu, Xavier, Rodon, Philippe, Roussel, Murielle, Azaïs, Isabelle, Doyen, Chantal, Slama, Borhane, Manier, Salomon, Decaux, Olivier, Pertesi, Maroulio, Beaumont, Marie, Caillot, Denis, Boyle, Eileen M, Cliquennois, Manuel, Cony-Makhoul, Pascale, Doncker, Anne-Violaine, Dorvaux, Véronique, Petillon, Marie Odile, Fontan, Jean, Hivert, Bénédicte, Leduc, Isabelle, Leyronnas, Cécile, Macro, Margaret, Maigre, Michel, Mariette, Clara, Mineur, Philippe, Rigaudeau, Sophie, Royer, Bruno, Vincent, Laure, Mckay, James, Perrial, Emeline, and Garderet, Laurent

Abstract

Familial forms of monoclonal gammopathy, defined as multiple myeloma (MM) or Monoclonal Gammopathy of Undetermined Significance (MGUS), are relatively infrequent and most series reported in the literature describe a limited number of families. MM rarely occurs in a familial context. MGUS is observed much more commonly, which can in some cases evolve toward full-blown MM. Although recurrent cytogenetic abnormalities have been described in tumor cells of sporadic cases of MM, the pathogenesis of familial MM remains largely unexplained. In order to identify genetic factors predisposing to familial monoclonal gammopathy, the Intergroupe Francophone du Myélome identified 318 families with at least two confirmed cases of monoclonal gammopathy. There were 169 families with parent/child pairs and 164 families with cases in at least two siblings, compatible with an autosomal transmission. These familial cases were compared with sporadic cases who were matched for age at diagnosis, sex and immunoglobulin isotype, with 10 sporadic cases for each familial case. The gender distribution, age and immunoglobulin subtypes of familial cases were unremarkable in comparison to sporadic cases. With a median follow-up of 7.4 years after diagnosis, the percentage of MGUS cases having evolved to MM was 3%. The median overall survival of the 148 familial MM cases was longer than that of matched sporadic cases, with projected values of 7.6 and 16.1 years in patients older and younger than 65 years, respectively. These data suggest that familial cases of monoclonal gammopathy are similar to sporadic cases in terms of clinical presentation and carry a better prognosis.

Published
2023

16. Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study

Author

Dumontet, Charles, primary, Demangel, Delphine, additional, Galia, Perrine, additional, Karlin, Lionel, additional, Roche, Laurent, additional, Fauvernier, Mathieu, additional, Golfier, Camille, additional, Laude, Marie‐Charlotte, additional, Leleu, Xavier, additional, Rodon, Philippe, additional, Roussel, Murielle, additional, Azaïs, Isabelle, additional, Doyen, Chantal, additional, Slama, Borhane, additional, Manier, Salomon, additional, Decaux, Olivier, additional, Pertesi, Maroulio, additional, Beaumont, Marie, additional, Caillot, Denis, additional, Boyle, Eileen M., additional, Cliquennois, Manuel, additional, Cony‐Makhoul, Pascale, additional, Doncker, Anne‐Violaine, additional, Dorvaux, Véronique, additional, Petillon, Marie Odile, additional, Fontan, Jean, additional, Hivert, Bénédicte, additional, Leduc, Isabelle, additional, Leyronnas, Cécile, additional, Macro, Margaret, additional, Maigre, Michel, additional, Mariette, Clara, additional, Mineur, Philippe, additional, Rigaudeau, Sophie, additional, Royer, Bruno, additional, Vincent, Laure, additional, Mckay, James, additional, Perrial, Emeline, additional, and Garderet, Laurent, additional

Published
2023
Full Text
View/download PDF

17. Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; &lt; 80 Years). IFM2020-05/Benefit

Author

Bobin, Arthur, primary, Lambert, Jerome, additional, Perrot, Aurore, additional, Manier, Salomon, additional, Montes, Lydia, additional, Jaccard, Arnaud, additional, Karlin, Lionel, additional, Godmer, Pascal, additional, Caillot, Denis, additional, Hulin, Cyrille, additional, Chalopin, Thomas, additional, Roul, Christophe, additional, Mariette, Clara, additional, Rigaudeau, Sophie, additional, Dingremont, Claire, additional, Santagostino, Alberto, additional, Dib, Mamoun, additional, Macro, Margaret, additional, Tiab, Mourad, additional, Laribi, Kamel, additional, Bourgeois-Petit, Emmanuelle, additional, Calmettes, Claire, additional, Orsini, Frederique, additional, Tabrizi, Reza, additional, Vincent, Laure, additional, Mohty, Mohamad, additional, Touzeau, Cyrille, additional, Corre, Jill, additional, Moreau, Philippe, additional, Facon, Thierry, additional, Avet Loiseau, Herve, additional, and Leleu, Xavier, additional

Published
2022
Full Text
View/download PDF

18. Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03

Author

Bobin, Arthur, primary, Lambert, Jerome, additional, Ragot, Stéphanie, additional, Perrot, Aurore, additional, Manier, Salomon, additional, Karlin, Lionel, additional, Caillot, Denis, additional, Hulin, Cyrille, additional, Benboubker, Lotfi, additional, Araujo, Carla, additional, Fontan, Jean, additional, Braun, Thorsten, additional, Mariette, Clara, additional, Scherman, Elodie, additional, Decaux, Olivier, additional, Blade, jean Sebastien, additional, Keddar, Faida, additional, Roul, Christophe, additional, Dib, Mamoun, additional, Corre, Jill, additional, Orsini, Frederique, additional, Vincent, Laure, additional, Mohty, Mohamad, additional, Touzeau, Cyrille, additional, Moreau, Philippe, additional, Avet Loiseau, Herve, additional, and Leleu, Xavier, additional

Published
2022
Full Text
View/download PDF

19. Low Non Relapse Mortality and Good Hematological Response after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients with Renal Insufficiency at Transplant: A Prospective Société Francaise De Greffe De Moelle-Thérapie Cellulaire Observational Study

Author

Garderet, Laurent, primary, Ouldjeriouat, Hafida, additional, Bekadja, Mohamed-Amine, additional, Daguenet, Elisabeth, additional, Vincent, Laure, additional, Roos Weil, Damien, additional, Vignon, Marguerite, additional, Mohty, Mohamad, additional, Abraham, Julie, additional, Escoffre-Barbe, Martine, additional, Lioure, Bruno, additional, Nacer, redhouane Ahmed, additional, Caillot, Denis, additional, Mariette, Clara, additional, Karlin, Lionel, additional, Morel, Pierre, additional, Gilis, Lila, additional, Leray, Emanuelle, additional, Blouet, Anaise, additional, Raus, Nicole, additional, Robin, Marie, additional, Boffa, jean Jacques, additional, Ronco, Pierre, additional, Rubio, Marie Thérèse, additional, Lambert, Jerome, additional, and Cornillon, Jérôme, additional

Published
2022
Full Text
View/download PDF

20. Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit

Author

Bobin, Arthur, Lambert, Jerome, Perrot, Aurore, Manier, Salomon, Montes, Lydia, Jaccard, Arnaud, Karlin, Lionel, Godmer, Pascal, Caillot, Denis, Hulin, Cyrille, Chalopin, Thomas, Roul, Christophe, Mariette, Clara, Rigaudeau, Sophie, Dingremont, Claire, Santagostino, Alberto, Dib, Mamoun, Macro, Margaret, Tiab, Mourad, Laribi, Kamel, Bourgeois-Petit, Emmanuelle, Calmettes, Claire, Orsini, Frederique, Tabrizi, Reza, Vincent, Laure, Mohty, Mohamad, Touzeau, Cyrille, Corre, Jill, Moreau, Philippe, Facon, Thierry, Avet Loiseau, Herve, and Leleu, Xavier

Published
2022
Full Text
View/download PDF

21. Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail RRMM patients: A multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).

Author

Leleu, Xavier, primary, Macro, Margaret, additional, Touzeau, Cyrille, additional, Mariette, Clara, additional, Manier, Salomon, additional, Brechignac, Sabine, additional, Vincent, Laure, additional, Hebraud, Benjamin, additional, Decaux, Olivier, additional, Schulmann, Samantha, additional, Lenoir, Caroline, additional, Godmer, Pascal, additional, Farge, Agathe, additional, Peyro Saint Paul, Laure, additional, and Parienti, Jean-Jacques, additional

Published
2022
Full Text
View/download PDF

22. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.

Author

UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Roussel, Murielle, Lauwers-Cances, Valérie, Macro, Margaret, Leleu, Xavier, Royer, Bruno, Hulin, Cyrille, Karlin, Lionel, Perrot, Aurore, Touzeau, Cyrille, Chrétien, Marie-Lorraine, Rigaudeau, Sophie, Dib, Mamoun, Nicolas-Virelizier, Emmanuelle, Escoffre-Barbe, Martine, Belhadj, Karim, Mariette, Clara, Stoppa, Anne-Marie, Araujo, Carla, Doyen, Chantal, Fontan, Jean, Kolb, Brigitte, Garderet, Laurent, Brechignac, Sabine, Malfuson, Jean-Valère, Jaccard, Arnaud, Lenain, Pascal, Borel, Cécile, Hebraud, Benjamin, Benbrahim, Omar, Dorvaux, Véronique, Manier, Salomon, Augeul-Meunier, Karine, Vekemans, Marie-Christiane, Randriamalala, Edouard, Chaoui, Driss, Caers, Jo, Chaleteix, Carine, Benboubker, Lofti, Vincent, Laure, Glaisner, Sylvie, Zunic, Patricia, Slama, Borhane, Eveillard, Jean-Richard, Humbrecht-Kraut, Catherine, Morel, Véronique, Mineur, Philippe, Eisenmann, Jean-Claude, Demarquette, Hélène, Richez, Valentine, Vignon, Marguerite, Caillot, Denis, Facon, Thierry, Moreau, Philippe, Colin, Anne-Laurène, Olivier, Pascale, Wuilleme, Soraya, Avet-Loiseau, Hervé, Corre, Jill, Attal, Michel, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Roussel, Murielle, Lauwers-Cances, Valérie, Macro, Margaret, Leleu, Xavier, Royer, Bruno, Hulin, Cyrille, Karlin, Lionel, Perrot, Aurore, Touzeau, Cyrille, Chrétien, Marie-Lorraine, Rigaudeau, Sophie, Dib, Mamoun, Nicolas-Virelizier, Emmanuelle, Escoffre-Barbe, Martine, Belhadj, Karim, Mariette, Clara, Stoppa, Anne-Marie, Araujo, Carla, Doyen, Chantal, Fontan, Jean, Kolb, Brigitte, Garderet, Laurent, Brechignac, Sabine, Malfuson, Jean-Valère, Jaccard, Arnaud, Lenain, Pascal, Borel, Cécile, Hebraud, Benjamin, Benbrahim, Omar, Dorvaux, Véronique, Manier, Salomon, Augeul-Meunier, Karine, Vekemans, Marie-Christiane, Randriamalala, Edouard, Chaoui, Driss, Caers, Jo, Chaleteix, Carine, Benboubker, Lofti, Vincent, Laure, Glaisner, Sylvie, Zunic, Patricia, Slama, Borhane, Eveillard, Jean-Richard, Humbrecht-Kraut, Catherine, Morel, Véronique, Mineur, Philippe, Eisenmann, Jean-Claude, Demarquette, Hélène, Richez, Valentine, Vignon, Marguerite, Caillot, Denis, Facon, Thierry, Moreau, Philippe, Colin, Anne-Laurène, Olivier, Pascale, Wuilleme, Soraya, Avet-Loiseau, Hervé, Corre, Jill, and Attal, Michel

Abstract

High-dose melphalan (HDM) and transplantation are recommended for eligible patients with multiple myeloma. No other conditioning regimen has proven to be more effective and/or safer. We previously reported in a phase 2 study that bortezomib can safely and effectively be combined with HDM (Bor-HDM), with a 32% complete response (CR) rate after transplantation. These data supported a randomized phase 3 trial. Randomization was stratified according to risk and response to induction: 300 patients were enrolled, and 154 were allocated to the experimental arm (ie, arm A) with bortezomib (1 mg/m2 intravenously [IV]) on days -6, -3, +1, and +4 and melphalan (200 mg/m2 IV) on day -2. The control arm (ie, arm B) consisted of HDM alone (200 mg/m2 IV). There were no differences in stringent CR + CR rates at day 60 posttransplant (primary end point): 22.1% in arm A vs 20.5% in arm B (P = .844). There were also no differences in undetectable minimum residual disease rates: 41.3% vs 39.4% (P = .864). Median progression-free survival was 34.0 months for arm A vs 29.6 months for arm B (adjusted HR, 0.82; 95% CI, 0.61-1.13; P = .244). The estimated 3-year overall survival was 89.5% in both arms (hazard ratio, 1.28; 95% CI, 0.62-2.64; P = .374). Sixty-nine serious adverse events occurred in 18.7% of Bor-HDM-treated patients (vs 13.1% in HDM-treated patients). The proportion of grade 3/4 AEs was similar within the 2 groups (72.0% vs 73.1%), mainly (as expected) blood and gastrointestinal disorders; 4% of patients reported grade 3/4 or painful peripheral neuropathy in arm A (vs 1.5% in arm B). In this randomized phase 3 study, a conditioning regimen with Bor-HDM did not improve efficacy end points or outcomes compared with HDM alone. The original trial was registered at www.clinicaltrials.gov as #NCT02197221.

Published
2022

23. Ixazomib and Daratumumab without Dexamethasone (I-Dara) in Elderly Frail RRMM Patients. a Multicenter Phase 2 Study (IFM 2018-02) of the Intergroupe Francophone Du Myélome (IFM)

Author

Macro, Magaret, primary, Touzeau, Cyrille, additional, Mariette, Clara, additional, Manier, Salomon, additional, Brechignac, Sabine, additional, Vincent, Laure, additional, Hebraud, Benjamin, additional, Decaux, Olivier, additional, Schulmann, Samantha, additional, Lenoir, Caroline Bureau, additional, Godmer, Pascal, additional, Parienti, Jean-Jacques, additional, and Leleu, Xavier, additional

Published
2021
Full Text
View/download PDF

24. Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myélome (IFM)

Author

Perrot, Aurore, primary, Lauwers-Cances, Valérie, additional, Touzeau, Cyrille, additional, Decaux, Olivier, additional, Hulin, Cyrille, additional, Macro, Magaret, additional, Stoppa, Anne-Marie, additional, Chretien, Marie Lorraine, additional, Karlin, Lionel, additional, Mariette, Clara, additional, Jacquet, Caroline, additional, Roussel, Murielle, additional, Guillemot, Coralie, additional, Devlamynck, Laure, additional, Avet-Loiseau, Hervé, additional, Moreau, Philippe, additional, and Attal, Michel, additional

Published
2021
Full Text
View/download PDF

25. Multicenter Open Label Phase 2 Study of Quadruplet-Based Regimen Iskpd (isatuximab plus pomalidomide and dexamethasone with carfilzomib) in Early Relapsed or Refractory Multiple Myeloma - IFM2018-03

Author

Bobin, Arthur, Lambert, Jerome, Ragot, Stéfanie, Perrot, Aurore, Manier, Salomon, Karlin, Lionel, Caillot, Denis, Benboubker, Lotfi, Chalopin, Thomas, Araujo, Carla, Fontan, Jean, Braun, Thorsten, Mariette, Clara, Scherman, Elodie, Decaux, Olivier, Blade, jean Sebastien, Keddar, Faiza, Roul, Christophe, Dib, Mamoun, Corre, Jill, Orsini Piocelle, Frederique, Vincent, Laure, Touzeau, Cyrille, Moreau, Philippe, Avet Loiseau, Herve, and Leleu, Xavier

Published
2023
Full Text
View/download PDF

26. Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05

Author

Bobin, Arthur, Hulin, Cyrille, Lambert, Jerome, Perrot, Aurore, Manier, Salomon, Montes, Lydia, Jaccard, Arnaud, Karlin, Lionel, Godmer, Pascal, Caillot, Denis, Chalopin, Thomas, Roul, Christophe, Mariette, Clara, Rigaudeau, Sophie, Delaunay, Jacques, Dingremont, Claire, Santagostino, Alberto, Dib, Mamoun, Macro, Margaret, Tiab, Mourad, Laribi, Kamel, Bourgeois Petit, Emmanuelle, Calmettes, Claire, Orsini Piocelle, Frederique, Bareau, Benoit, Tabrizi, Reza, Vincent, Laure, Mohty, Mohamad, Touzeau, Cyrille, Corre, Jill, Moreau, Philippe, Facon, Thierry, Avet Loiseau, Herve, and Leleu, Xavier

Published
2023
Full Text
View/download PDF

27. Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01

Author

Bobin, Arthur, Manier, Salomon, De Keizer, Joe, Hulin, Cyrille, Karlin, Lionel, Caillot, Denis, Mariette, Clara, Araujo, Carla, Arnulf, Bertrand, Bareau, Benoit, Belhadj Merzoug, Karim, Benboubker, Lotfi, Braun, Thorsten, Calmettes, Claire, Decaux, Olivier, Dib, Mamoun, Demarquette, Helene, Feugier, Pierre, Sonntag, Cécile, Jaccard, Arnaud, Lenain, Pascal, Macro, Margaret, Richez, Valentine, Tiab, Mourad, Vincent, Laure, Zerazhi, Hacene, Petillon, Marie-Odile, Touzeau, Cyrille, Perrot, Aurore, Moreau, Philippe, Facon, Thierry, Avet Loiseau, Herve, and Leleu, Xavier

Published
2023
Full Text
View/download PDF

29. Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience.

Author

UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Caulier, Alexis, Roussel, Murielle, Morel, Pierre, Lombion, Naelle, Branco, Benoît, Galtier, Jean, Hulin, Cyrille, Perrot, Aurore, Richez, Valentine, Michaud, Anne-Victoire, Touzeau, Cyrille, Doyen, Chantal, Mariette, Clara, Caillot, Denis, Harel, Stéphanie, Lenain, Pascal, Ivanoff, Sarah, Fontan, Jean, Stoppa, Anne-Marie, Manier, Salomon, Garderet, Laurent, Leleu, Xavier, Marolleau, Jean-Pierre, Arnulf, Bertrand, Avet-Loiseau, Hervé, Royer, Bruno, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Caulier, Alexis, Roussel, Murielle, Morel, Pierre, Lombion, Naelle, Branco, Benoît, Galtier, Jean, Hulin, Cyrille, Perrot, Aurore, Richez, Valentine, Michaud, Anne-Victoire, Touzeau, Cyrille, Doyen, Chantal, Mariette, Clara, Caillot, Denis, Harel, Stéphanie, Lenain, Pascal, Ivanoff, Sarah, Fontan, Jean, Stoppa, Anne-Marie, Manier, Salomon, Garderet, Laurent, Leleu, Xavier, Marolleau, Jean-Pierre, Arnulf, Bertrand, Avet-Loiseau, Hervé, and Royer, Bruno

Abstract

Multiple myeloma (MM) is rare in young patients, especially before age 40 years at diagnosis, representing <2% of all patients with MM. Little is known about the disease characteristics and prognosis of these patients. In this study, we examined 214 patients diagnosed with MM at age ≤40 years over 15 years, in the era of modern treatments. Among them, 189 patients had symptomatic MM. Disease characteristics were similar to older patients: 35% had anemia, 17% had renal impairment, and 13% had hypercalcemia. The staging was ISS-1 in 52.4%, ISS-2 in 27.5%, and ISS-3 in 20.1%. Overall, 18% of patients had high-risk cytogenetics [del 17p and/or t(4;14)]. Ninety percent of patients received intensive chemotherapy followed by autologous stem cell transplant, and 25% of patients had allogeneic stem cell transplant predominantly at time of relapse. The median follow-up was 76 months, the estimated median overall survival was 14.5 years, and the median progression free-survival was 41 months. In multivariate analysis, bone lesions (hazard ratio [HR], 3.95; P = .01), high ISS score (HR, 2.14; P = .03), and high-risk cytogenetics (HR, 4.54; P < .0001) were significant risk factors for poor outcomes. Among predefined time-dependent covariables, onset of progression (HR, 13.2; P < .0001) significantly shortened overall survival. At 5 years, relative survival compared with same age- and sex-matched individuals was 83.5%, and estimated standardized mortality ratio was 69.9 (95% confidence interval, 52.7-91.1), confirming that MM dramatically shortens the survival of young patients despite an extended survival after diagnosis.

Published
2021

30. Acceptable Toxicity and Good Hematological and Renal Responses after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients with Renal Insufficiency at Transplant: A Prospective SFGM-TC Observational Study

Author

Garderet, Laurent, primary, Ouldjeriouat, Hafida, additional, Bekadja, Mohamed-Amine, additional, Daguenet, Elisabeth, additional, Vincent, Laure, additional, roos Weil, Damien, additional, Vignon, Marguerite, additional, Mohty, Mohamad, additional, Abraham, Julie, additional, Escoffre-Barbe, Martine, additional, Lioure, Bruno, additional, Ahmed Nacer, Redhouane, additional, Caillot, Denis, additional, Mariette, Clara, additional, Karlin, Lionel, additional, Morel, Pierre, additional, Gilis, Lila, additional, Leray, Emanuelle, additional, Blouet, Anaise, additional, Raus, Nicole, additional, Robin, Marie, additional, Boffa, jean Jacques, additional, Ronco, Pierre, additional, Rubio, Marie Thérèse, additional, and Cornillon, Jérôme, additional

Published
2020
Full Text
View/download PDF

31. French National Retrospective Cohort of Hairy-Cell Leukemias: Risk of Second Malignancies after 10 Years of Follow-up

Author

Paillassa, Jérôme, primary, Cornet, Edouard, additional, Noel, Stephanie, additional, Tomowiak, Cecile, additional, Schmidt, Aline, additional, Lepretre, Stephane, additional, Vaudaux, Sandrine, additional, Dupuis, Jehan, additional, Devidas, Alain, additional, Bertrand, Joly, additional, Petitditdier, Charlotte, additional, Haiat, Stéphanie, additional, Mariette, Clara, additional, Thieblemont, Catherine, additional, Decaudin, Didier, additional, Drenou, Bernard, additional, Eisenmann, Jean Claude, additional, Ojeda, Mario, additional, Olivrie, Agnès, additional, Gourin, Marie-Pierre, additional, Lambotte, Olivier, additional, Hermine, Olivier, additional, Karsenti, Jean Michel, additional, Feugier, Pierre, additional, Vaillant, Willy, additional, Gutnecht, Jean, additional, Lippert, Eric, additional, Huysman, Fabienne, additional, Ghomari, Kamel, additional, Boubaya, Marouane, additional, Levy, Vincent, additional, Riou, Jérémie, additional, Damaj, Gandhi, additional, Hunault, Mathilde, additional, and Troussard, Xavier, additional

Published
2019
Full Text
View/download PDF

32. De novo adult acute myeloid leukemia patients’ display at diagnosis functional deregulation of redox balance correlated with molecular subtypes and overall survival

Author

Mondet, Julie, primary, Presti, Caroline Lo, additional, Garrel, Catherine, additional, Skaare, Kristina, additional, Mariette, Clara, additional, Carras, Sylvain, additional, Park, Sophie, additional, Carré, Martin, additional, Bulabois, Claude-Eric, additional, Molina, Lysiane, additional, Gressin, Rémy, additional, Thiebaut, Anne, additional, Courby, Stéphane, additional, Socoro-Yuste, Nuria, additional, Faure, Patrice, additional, Leer, Anne Mc, additional, Cahn, Jean-Yves, additional, and Mossuz, Pascal, additional

Published
2019
Full Text
View/download PDF

33. Hairy Cell Leukemia: Results of the French Retrospective Cohort After 10 Years of Follow Up

Author

Paillassa, Jérôme, primary, Cornet, Edouard, additional, Tomowiak, Cécile, additional, Tanguy-Schmidt, Aline, additional, Lepretre, Stéphane, additional, Dupuis, Jehan, additional, Feugier, Pierre, additional, Devidas, Alain, additional, Mariette, Clara, additional, Leblond, Véronique, additional, Thieblemont, Catherine, additional, Decaudin, Didier, additional, Sutton, Laurent, additional, Gyan, Emmanuel, additional, Eisenmann, Jean-Claude, additional, Cony-Makhoul, Pascale, additional, Vaillant, Willy, additional, Olivrie, Agnès, additional, Huysman, Fabienne, additional, Lambotte, Olivier, additional, Hermine, Olivier, additional, Lippert, Eric, additional, and Troussard, Xavier, additional

Published
2019
Full Text
View/download PDF

34. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Author

Richardson, Paul G, primary, Oriol, Albert, additional, Beksac, Meral, additional, Liberati, Anna Marina, additional, Galli, Monica, additional, Schjesvold, Fredrik, additional, Lindsay, Jindriska, additional, Weisel, Katja, additional, White, Darrell, additional, Facon, Thierry, additional, San Miguel, Jesus, additional, Sunami, Kazutaka, additional, O'Gorman, Peter, additional, Sonneveld, Pieter, additional, Robak, Pawel, additional, Semochkin, Sergey, additional, Schey, Steve, additional, Yu, Xin, additional, Doerr, Thomas, additional, Bensmaine, Amine, additional, Biyukov, Tsvetan, additional, Peluso, Teresa, additional, Zaki, Mohamed, additional, Anderson, Kenneth, additional, Dimopoulos, Meletios, additional, Abildgaard, Niels, additional, Adler, Howard, additional, Altuntas, Fevzi, additional, Akay, Olga Meltem, additional, Amin, Bipinkumar, additional, Anagnostopoulos, Achilleas, additional, Anderson, Larry, additional, Anttila, Pekka, additional, Araujo, Carla, additional, Arce-Lara, Carlos, additional, Aydin, Yildiz, additional, Basu, Supratik, additional, Battini, Ramakrishna, additional, Beeker, Thaddeus, additional, Benboubker, Lotfi, additional, Ben-Yehuda, Dina, additional, Bladé, Joan, additional, Blau, Igor Wolfgang, additional, Boccia, Ralph, additional, Burke, Lillian, additional, Byeff, Peter, additional, Cascavilla, Nicola, additional, Cavo, Michele, additional, Chantry, Andrew, additional, Charles, Yen, additional, Chaudhry, Arvind, additional, Corso, Alessandro, additional, Coyne, Mark, additional, De Arriba, Felipe, additional, Delimpasi, Sosana, additional, Desjardins, Pierre, additional, Dhakal, Binod, additional, Di Bartolomeo, Paolo, additional, Di Raimondo, Francesco, additional, Dürig, Jan, additional, Engelhardt, Monika, additional, Escoffre-Barbe, Martine, additional, Esteves, Graca, additional, Flogegard, Max, additional, Gabrail, Nashat, additional, Gamberi, Barbara, additional, Garrison, Mitchell, additional, Gay, Julie, additional, Gisslinger, Heinz, additional, Goldschmidt, Hartmut, additional, Goncalves, Cristina, additional, Gressot, Laurent, additional, Grosicki, Sebastian, additional, Hanna, Wahid, additional, Hayden, Patrick, additional, Henriques Bernardo, Maria Manuela, additional, Hermann, Robert, additional, Holden, Viran, additional, Honkalehto, Kirsti, additional, Huben, Marianne, additional, Huffman, John, additional, Hunter, Hannah, additional, Hus, Marek, additional, Jagasia, Madan, additional, Jagganath, Sundar, additional, Janakiram, Murali, additional, Jaiyesimi, Ishmael, additional, Jenner, Matthew, additional, João, Cristina, additional, Johnson, Peter, additional, Jurcyszyn, Artur, additional, Kalayoğlu Beşişik, Sevgi, additional, Kambhampati, Suman, additional, Kanate, Abraham, additional, Karadoğan, Ihsan, additional, Khojasteh, Ali, additional, Kirkel, Dean, additional, Komarnicki, Mieczyslaw, additional, Krauth, Maria-Theresa, additional, Kuriakose, Phillip, additional, Larocca, Alessandra, additional, Lauri, Birgitta, additional, Leleu, Xavier, additional, Lucio, Paulo, additional, Luppi, Mario, additional, Mangiacavalli, Silvia, additional, Mariette, Clara, additional, Matsue, Kosei, additional, Mellqvist, Ulf-Henri, additional, Mendeleeva, Larisa, additional, Meshad, Michael, additional, Miller, Carole, additional, Mohrbacher, Ann, additional, Moreau, Philippe, additional, Morelli, Anna Maria, additional, Müldür, Ercan, additional, Naassan, Anthony, additional, Nahi, Hareth, additional, Nair, Rajesh, additional, O'Dwyer, Mike, additional, Öngören Aydin, Seniz, additional, Openshaw, Thomas, additional, O'Rourke, Timothy, additional, Osswald, Michael, additional, Overton, Lindsay, additional, Pati, Asmin, additional, Pavic, Michel, additional, Pegourie, Brigitte, additional, Pehlivan, Mustafa, additional, Pierola, Ana Alfonso, additional, Plesner, Torben, additional, Pluta, Andrzej, additional, Rabin, Neil, additional, Ramasamy, Karthik, additional, Rambaldi, Alessandro, additional, Rodriguez, Paula, additional, Röllig, Christoph, additional, Rosenblatt, Jacalyn, additional, Rosenbluth, Jonathan, additional, Salomo, Morten, additional, Samoylova, Olga, additional, Sastre Moral, Jose, additional, Sati, Hamdi, additional, Selleri, Carmine, additional, Shafeek, Salim, additional, Shinagawa, Atsushi, additional, Sleckman, Bethany, additional, Smith, Clay, additional, Sonmez, Mehmet, additional, Stone, Chester, additional, Streetly, Matthew, additional, Suzuki, Kenshi, additional, Taetle, Raymond, additional, Tafuri, Agostino, additional, Takezako, Naoki, additional, Teke, Hava Üsküdar, additional, Vapaatalo, Mirja, additional, Vassilopoulos, George, additional, Verma, Amit, additional, Vidito, Sarah, additional, Viterbo, Luisa, additional, Vural, Filiz, additional, Wang, Xiang Sean, additional, Yağci, Munci, additional, and Yee, Andrew, additional

Published
2019
Full Text
View/download PDF

35. Adult patients with de novo acute myeloid leukemia show a functional deregulation of redox balance at diagnosis which is correlated with molecular subtypes and overall survival

Author

Mondet, Julie, primary, Presti, Caroline Lo, additional, Garrel, Catherine, additional, Skaare, Kristina, additional, Mariette, Clara, additional, Carras, Sylvain, additional, Park, Sophie, additional, Carré, Martin, additional, Bulabois, Claude-Eric, additional, Molina, Lysiane, additional, Gressin, Rémy, additional, Thiebaut, Anne, additional, Courby, Stéphane, additional, Socoro-Yuste, Nuria, additional, Faure, Patrice, additional, Leer-Florin, Anne Mc, additional, Cahn, Jean-Yves, additional, and Mossuz, Pascal, additional

Published
2019
Full Text
View/download PDF

36. Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes

Author

Park, Sophie, primary, Kosmider, Olivier, additional, Maloisel, Frédéric, additional, Drenou, Bernard, additional, Chapuis, Nicolas, additional, Lefebvre, Thibaud, additional, Karim, Zoubida, additional, Puy, Hervé, additional, Alary, Anne Sophie, additional, Ducamp, Sarah, additional, Verdier, Frédérique, additional, Bouilloux, Cécile, additional, Rousseau, Alice, additional, Jacob, Marie-Christine, additional, Debliquis, Agathe, additional, Charpentier, Agnes, additional, Gyan, Emmanuel, additional, Anglaret, Bruno, additional, Leyronnas, Cecile, additional, Corm, Selim, additional, Slama, Borhane, additional, Cheze, Stephane, additional, Laribi, Kamel, additional, Amé, Shanti, additional, Rose, Christian, additional, Lachenal, Florence, additional, Toma, Andrea, additional, Pica, Gian Matteo, additional, Carre, Martin, additional, Garban, Frédéric, additional, Mariette, Clara, additional, Cahn, Jean-Yves, additional, Meunier, Mathieu, additional, Herault, Olivier, additional, Fenaux, Pierre, additional, Wagner-Ballon, Orianne, additional, Bardet, Valerie, additional, Dreyfus, Francois, additional, and Fontenay, Michaela, additional

Published
2018
Full Text
View/download PDF

37. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT

Author

Gagelmann, Nico, primary, Eikema, Diderik-Jan, additional, Iacobelli, Simona, additional, Koster, Linda, additional, Nahi, Hareth, additional, Stoppa, Anne-Marie, additional, Masszi, Tamás, additional, Caillot, Denis, additional, Lenhoff, Stig, additional, Udvardy, Miklos, additional, Crawley, Charles, additional, Arcese, William, additional, Mariette, Clara, additional, Hunter, Ann, additional, Leleu, Xavier, additional, Schipperus, Martin, additional, Delforge, Michel, additional, Pioltelli, Pietro, additional, Snowden, John A., additional, Itälä-Remes, Maija, additional, Musso, Maurizio, additional, van Biezen, Anja, additional, Garderet, Laurent, additional, and Kröger, Nicolaus, additional

Published
2018
Full Text
View/download PDF

38. Dyserythropoiesis Evaluated by Red Score and Hepcidin/Ferritin Levels Predicts Response to Erythropoietin in Lower Risk Myelodysplastic Syndromes

Author

Park, Sophie, primary, Kosmider, Olivier, additional, Maloisel, Frederic, additional, Drenou, Bernard, additional, Chapuis, Nicolas, additional, Lefebvre, Thibaud, additional, Karim, Zoubida, additional, Puy, Hervé, additional, Alary, Anne Sophie, additional, Rousseau, Alice, additional, Bouilloux, Cecile, additional, Ducamp, Sarah, additional, Verdier, Frederique, additional, Jacob, Marie-Christine, additional, Debliquis, Agathe, additional, Charpentier, Agnes, additional, Gyan, Emmanuel, additional, Anglaret, Bruno, additional, Leyronnas, Cecile, additional, Corm, Selim, additional, Slama, Borhane, additional, Cheze, Stephane, additional, Laribi, Kamel, additional, Amé, Shanti, additional, Rose, Christian, additional, Lachenal, Florence, additional, Toma, Andrea, additional, Pica, Gian Matteo, additional, Carre, Martin, additional, Garban, Frederic, additional, Mariette, Clara, additional, Cahn, Jean-Yves, additional, Meunier, Mathieu, additional, Herault, Olivier, additional, Fenaux, Pierre, additional, Wagner-Ballon, Orianne, additional, Bardet, Valerie, additional, Fontenay, Michaela, additional, and Dreyfus, Francois, additional

Published
2018
Full Text
View/download PDF

39. Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods

Author

Corre, Jill, Perrot, Aurore, Hulin, Cyrille, Caillot, Denis, Stoppa, Anne-Marie, Facon, Thierry, Leleu, Xavier, Dib, Mamoun, Karlin, Lionel, Moreau, Philippe, Mohty, Mohamad, Mariette, Clara, Fontan, Jean, Marolleau, Jean-Pierre, Demarquette, Hélène, Slama, Borane, Voillat, Laurent, Macro, Margaret, Orsini-Piocelle, Frédérique, Brechignac, Sabine, Rey, Philippe, Collet, Philippe, Tiab, Mourad, Belhadj, Karim, Lifermann, François, Clement-Filliatre, Lauriane, Sohn, Claudine, Richez, Valentine, and Avet-loiseau, Hervé

Published
2021
Full Text
View/download PDF

40. Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial

Author

Boyle, Eileen Mary, primary, Petillon, Marie-Odile, additional, Herbaux, Charles, additional, Mimouni, Johanna, additional, Leleu, Xavier, additional, Karlin, Lionel, additional, Doyen, Chantal, additional, Wetterwald, Marc, additional, Roussel, Muriel, additional, Hulin, Cyrille, additional, Royer, Bruno, additional, Macro, Margaret, additional, Moreau, Philippe, additional, Fostier, Karel, additional, Dib, Mamoun, additional, Brechignac, Sabine, additional, Bureau, Caroline, additional, Marit, Gerald, additional, Tempescul, Adrian, additional, Chretien, Marie Lorraine, additional, Zarnitsky, Charles, additional, Fohrer, Cecile, additional, Perrot, Aurore, additional, Benboubker, Lotfi, additional, Voillat, Laurent, additional, Malfuson, Jean Valere, additional, Mariette, Clara, additional, Tiab, Mourad, additional, Rigaudeau, Sophie, additional, Jaccard, Arnaud, additional, Stoppa, Anne-Marie, additional, Vincent, Laure, additional, Eisenmann, Jean Claude, additional, Frenzel, Laurent, additional, Arnulf, Bertrand, additional, Mohty, Mohamad, additional, Rodon, Philippe, additional, Kolb, Brigitte, additional, Decaux, Olivier, additional, Godmer, Pascal, additional, Beauvais, David, additional, Carpentier, Benjamin, additional, Bonnet, Sarah, additional, Longval, Thomas, additional, Dewevre, Mathieu, additional, Avet-Loiseau, Herve, additional, Attal, Michel, additional, Schraen, Susanna, additional, and Facon, Thierry, additional

Published
2016
Full Text
View/download PDF

41. Epidemiology of Bacterial Infections during Induction Chemotherapy in Adult Patients with Acute Lymphoblastic Leukemia (ALL): Analysis of the Graall-2005 Study

Author

Honeyman, Fressia, primary, Tavernier, Emmanuelle, additional, Richez, Valentine, additional, Leguay, Thibaut, additional, Tinquaut, Fabien, additional, Le Clech, Lenaïg, additional, Hicheri, Yosr, additional, Lepretre, Stephane, additional, Bilger, Karin, additional, Baerlocher, Gabriela M., additional, Berceanu, Ana, additional, Gallego Hernanz, Maria Pilar, additional, Cacheux, Victoria, additional, Chalandon, Yves, additional, Lhéritier, Véronique, additional, Mariette, Clara, additional, Legrand, Faezeh, additional, Guyotat, Denis, additional, Ifrah, Norbert, additional, Dombret, Hervé, additional, and Thomas, Xavier, additional

Published
2016
Full Text
View/download PDF

42. Impact of Extramedullary Disease in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: A Study By the EBMT Chronic Malignancies Working Party

Author

Gagelmann, Nico, primary, Iacobelli, Simona, additional, Koster, Linda, additional, Nahi, Hareth, additional, Stoppa, Anne-Marie, additional, Masszi, Tamás, additional, Caillot, Denis, additional, Lenhoff, Stig, additional, Udvardy, Miklos, additional, Crawley, Charles, additional, Arcese, William, additional, Mariette, Clara, additional, Hunter, Ann, additional, Leleu, Xavier, additional, Schipperus, Martin, additional, Delforge, Michel, additional, Pioltelli, Pietro, additional, Snowden, John A, additional, Itälä-Remes, Maija, additional, Musso, Maurizio, additional, Garderet, Laurent, additional, and Kröger, Nicolaus, additional

Published
2016
Full Text
View/download PDF

43. Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study

Author

Mariette, Clara, primary, Tavernier, Emmanuelle, additional, Hocquet, Didier, additional, Huynh, Anne, additional, Isnard, Françoise, additional, Legrand, Faezeh, additional, Lhéritier, Véronique, additional, Raffoux, Emmanuel, additional, Dombret, Hervé, additional, Ifrah, Norbert, additional, Cahn, Jean-Yves, additional, and Thiébaut, Anne, additional

Published
2016
Full Text
View/download PDF

44. Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study.

Author

Mariette, Clara, Tavernier, Emmanuelle, Hocquet, Didier, Huynh, Anne, Isnard, Françoise, Legrand, Faezeh, Lhéritier, Véronique, Raffoux, Emmanuel, Dombret, Hervé, Ifrah, Norbert, Cahn, Jean-Yves, and Thiébaut, Anne

Subjects
*LYMPHOBLASTIC leukemia, *MYCOSES, *ASPERGILLOSIS, *INVASIVE candidiasis, *FUSARIUM
Abstract

Little data have been published concerning invasive fungal infections during treatment of acute lymphoblastic leukemia (ALL). Patients included between May 2006 and October 2012 in the multicenter phase III trial for newly diagnosed ALL (GRAALL-2005) were retrospectively reviewed for the occurrence of IFI using the EORTC modified criteria. These patients did not routinely receive antifungal prophylaxis. Among 969 patients included (median age 47 years), 65 (6.7%) developed IFI during induction chemotherapy: 26 (3.3%) invasive aspergillosis (IA), 33 (3.4%) invasive candidiasis (IC) and six other IFI. For IA, the median time between induction therapy and IA diagnosis was 20 days. Diagnosis was probable in 22 cases and proven in four. Aspergillus antigen in serum was tested in all cases and positive in 24. Overall 12-week mortality after diagnosis of IA was 5/26 and attributable mortality related to the infection was 4/26 (15.4%). For IC, the median time between induction therapy and diagnosis was 19 days. Diagnosis was proven in 29 episodes. Candida albicans was the major pathogen in yeast infections (16/27). Overall 12-week mortality after diagnosis of IC was 8/33 (24.2%) and attributable mortality related to the infection was 7/33. The median delay between induction chemotherapy initiation and attributable death related to IC was 15 days. These findings may help to optimize the future management of ALL patients, and as in AML advocate systematic monitoring and the development of prophylactic or preemptive antifungal treatments. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

45. Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).

Author

Touzeau, Cyrille, Leleu, Xavier P, Mariette, Clara, Manier, Salomon, Brechignac, Sabine, Vincent, Laure, Hebraud, Benjamin, Decaux, Olivier, Schulmann, Samantha, Lenoir, Caroline, Godmer, Pascal, Farge, Agathe, Peyro Saint Paul, Laure, Parienti, Jean-Jacques, and Macro, Margaret

Published
2023
Full Text
View/download PDF

46. Epidemiology Of Invasive Aspergillosis (IA) During Induction Therapy In Adults With Acute Lymphoblastic Leukemia (ALL): A Graall-2005 Study

Author

Mariette, Clara, primary, Thiebaut, Anne, additional, Cahn, Jean-Yves, additional, Hocquet, Didier, additional, Huynh, Agnes, additional, Isnard, Françoise, additional, Legrand, Faezeh, additional, Lhéritier, Véronique, additional, Tavernier, Emmanuelle, additional, Raffoux, Emmanuel, additional, Ifrah, Norbert, additional, Schmidt, Aline, additional, and Dombret, Herve, additional

Published
2013
Full Text
View/download PDF

47. Allogeneic Stem Cell Transplantation In Philadelphia Negative Myeloproliferative Or Myelodysplastic/Myeloproliferative Neoplasms: A Retrospective Analysis From The Societe Française De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)

Author

Cahu, Xavier, primary, Chevallier, Patrice, additional, Clavert, Aline, additional, Suarez, Felipe, additional, Michallet, Mauricette, additional, Fegueux, Nathalie, additional, Vigouroux, Stephane, additional, Blaise, Didier, additional, Socié, Gérard, additional, Mariette, Clara, additional, Bilger, Karin, additional, Yakoub-Agha, Ibrahim, additional, Peffault de Latour, Regis, additional, and Mohty, Mohamad, additional

Published
2013
Full Text
View/download PDF

48. Early Deaths (ED) in Acute Promyelocytic Leukemia (APL) in France: A Retrospective Multicenter Study in 355 Patients (pts)

Author

Rahmé, Rami, primary, Thomas, Xavier, additional, Recher, Christian, additional, Vey, Norbert, additional, Delaunay, Jacques, additional, Deconinck, Eric, additional, Bordessoule, Dominique, additional, Micol, Jean-Baptiste, additional, Stamatoullas, Aspasia, additional, Mariette, Clara, additional, Pautas, Cécile, additional, Bories, Pierre, additional, Marolleau, Jean-Pierre, additional, Hunault-Berger, Mathilde, additional, Fegueux, Nathalie, additional, Raffoux, Emmanuel, additional, Dombret, Hervé, additional, Chevret, Sylvie, additional, Degos, Laurent, additional, Fenaux, Pierre, additional, and Ades, Lionel, additional

Published
2012
Full Text
View/download PDF

49. Hairy Cell Leukemia: Evaluation of Long-Term Outcomes in 487 Patients

Author

Cornet, Edouard, primary, Tomowiak, Cécile, additional, Tanguy-Schmidt, Aline, additional, Leprêtre, Stéphane, additional, Dupuis, Jehan, additional, Feugier, Pierre, additional, Devidas, Alain, additional, Mariette, Clara, additional, Leblond, Véronique, additional, Thieblemont, Catherine, additional, Validire-Charpy, Patricia, additional, Sutton, Laurent, additional, Gyan, Emmanuel, additional, Eisenmann, Jean-Claude, additional, and Troussard, Xavier, additional

Published
2012
Full Text
View/download PDF

50. High Intermittent Dose of Chlorambucil Associated with Rituximab Is a Promising Treatment of Elderly Patients with Indolent Lymphoma.

Author

Andrianarison, Laingo, primary, Courby, Stephane, additional, Fabre, Blandine, additional, Molina, Lysiane, additional, Legrand, Valerie, additional, Bandelier, Brigitte Pegourie, additional, Simon, Audrey, additional, Mariette, Clara, additional, Vettier, Claire, additional, Lefebvre, Christine, additional, Garban, Frederic, additional, Bulabois, Claude Eric, additional, Thiebaut, Anne, additional, Cahn, Jean Yves, additional, and Gressin, Remy, additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results